Difference between revisions of "Main Page"
Line 35: | Line 35: | ||
Being '''intimately familiar''' with these site links will probably raise your ''clinical trialist IQ'' by 20 points | Being '''intimately familiar''' with these site links will probably raise your ''clinical trialist IQ'' by 20 points | ||
− | == Useful Wiki | + | == Useful (out-of-Wiki) Websites == |
− | + | Thorough knowledge of what's available on these other Websites is probably worth 20 added points to your 'Clinical Trialist IQ' | |
− | + | ||
− | + | :[[Funding Sources]] and other Key Info Resources | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
== Software that's essential for your efficiency == | == Software that's essential for your efficiency == |
Revision as of 15:20, 24 December 2007
Imaging Clinical Trials.
Imaging clinical trialists face complexities not shared by other clinicians conducting clinical experiments. Although much has been written on the subject of Clinical Trials http://en.wikipedia.org/wiki/Clinical_trial, this Wiki serves as a resource for those imaging professionals who need more than mere familiarity with the design and conduct of clinical trials. Its content arose from key modules of the mentoring program conducted jointly by RSNA and NCI for select young imaging faculty who plan careers as professional clinical trialists.
Consult the User's Guide for information on using the wiki software.----
Concepts and FAQ's addressed in this course
- How does a screening trial differ from a therapeutic trial?
- How does a randomized control trial (RCT) differ from an observational trial?
- Must the control arm of a therapeutic RCT always be a placebo?
- What distinguishes Phase 1, 2, 3 and 4 trials?
- What are ‘Phase 0’ trials and what role would imaging have in them?
- What data do you need to determine a statistically valid study size?
- When does a trial need a Data Safety Monitoring (DSM) board?
- What functions do interim and futility analyses serve?
- What are the definitions of type 1 and type 2 errors?
- How do you constitute an imaging central reading review panel and how does it function?
- What is the regulatory definition (e.g. FDA) of a “surrogate’ biomarker?
- How do “prognostic” biomarkers differ from ‘predictive’ markers?
- What happens if an ‘adverse event’ occurs to a study subject?
- What is the purpose of and 'interim analysis' and who conducts it?
Abbreviations and Definitions
- CR (Complete Response)
- DFS (Disease Free Survival)
- ORR (Objective Response Rate) In solid tumors it concludes a measurable reduction in target tumor mass as depicted by imaging
- OS (Overall Survival)
- PD (Progressive Disease)
- PR (Partial Response)
- PFS (Progression Free Survival)
- RR (Response Rate) represents data that implies an reduction of the amount of tumor burden and can include either reduced symptoms or shrinkage of measured tumor size or both.
- RECIST Response Evaluation Criteria for Imaging in Solid Tumors. A solid tumor measurement method that uses the sum or 'target tumor' linear diameter measures to estimate time-sequence changes in tumor volume
- SD (Stable Disease)
- TTP (Time to Progression)
- Target Lesions tumors visible at baseline that are measured sequentially over time by the RECIST criteria http://www.eortc.org/Recist/Default.htm
- WHO A solid tumor measurement method that uses two orthogonal tumor diameter measures to estimate time-sequence changes in tumor volume
Being intimately familiar with these site links will probably raise your clinical trialist IQ by 20 points
Useful (out-of-Wiki) Websites
Thorough knowledge of what's available on these other Websites is probably worth 20 added points to your 'Clinical Trialist IQ'
- Funding Sources and other Key Info Resources
Software that's essential for your efficiency
You can't be efficient until you have a thorough knowledge of the following software applications. Spend some time learning them intimately - it will be worth it.
- Acrobat Professional – especially when you need to extract text (Select Tool) and images (Advanced ->export all images); track changes (Comments & Markup); or publish a smaller, unchangeable PPT as a PDF;
- Word – convert to Adobe PDF using an Acrobat plug-in; Track changes (ctrl+shift+E); email document as a draft for comment; add images; has hierarchical outline view
- Endnote – links to Word; does its’ own PUBmed searching, constructs a complete bibliography and dynamically formats your references while you write
- PowerPoint (PPT) – you can incorporate and edit web pages and images for presentations. And it's an easy way to construct protocol flow schemas
- Quosa – http://www.quosa.com/ connects automatically to PubMed and extracts full article PDFs if you are allowed to do so by your institutional license.
Informed Consent and Ethics
Informed consent is an essential part of the ethical conduct of clinical trials. For more detailed discussion follow this link > Informed Consent
Trials: their types
- Phase 1 - less than 30 subjects - purpose to determine therapy dose and delivery
- Phase 2 - 100 or so subjects - to determine 'efficacy'
- Phase 3 - large numbers of subjects - to determine effect relative to standard therapy
- Phase 4 - large subject numbers - to determine ' efficaciousness' after therapy is in widespread use
- Phase 0 (a new category often using nuclear imaging or MRI) - less than a dozen subjects - to determine if a 'targeted therapy' reaches the intended disease tissue
Diagnostic Technology Assessment Trials
Diagnostic tests are conducted to determine whether cancer is present, where it is located and its stage. Some diagnostic trials compare two or more techniques to diagnose cancer and determine whether one technique is superior. Genetic tests are being evaluated as diagnostic tools to further classify cancers so as to direct therapies or improve treatments for people with specific genetic changes.
Basic Protocol Considerations
Clinical trials follow strict scientific guidelines. These guidelines clearly state the study’s design and who will be able to participate in the study (patient eligibility) Every trial has principal investigator(s). The principal investigator prepares a plan for the study (a protocol) which describes the clinical trial in complete detail. The protocol explains what the trial will do, how the study will be carried out, and why each part of the study is necessary. It includes information on:
- The importance and rationale that justifies the study
- A statistically justified cohort size (for each arm)
- Eligibility criteria (requirements may involve type of cancer, general health, age, prior therapy)
- The intervention or therapy being tested (e.g. drug dosage, etc.)
- What tests participants will have and how often (a ‘patient calendar’)
- What information will be gathered about the participants and how their privacy will be protected
- The participants options if they choose to withdraw
- A readable consent form (at an eighth-grade readability level)
- The endpoints (primary and secondary) and correlative studies
- Methods of analysis
- Regulatory requirements and reporting obligations
Investigational Drugs and Devices
Investigational means any drug or device not currently marketed in the US in the exact form that you are using for the exact indication for which you are using it. For example, updated device software is investigational, as is investigation of an marketed drug for a disease or histology that is not explicitly in the drug labeling. For more detailed discussion follow this link > Investigational Drugs & Devices
Biases and Their Control
Assessing predictive value of tests
Imaging as a Measure of Therapeutic Response
Suppose you were asked to devise an imaging acquisition protocol and analysis scheme for a new drug therapeutic trial that might be submitted to FDA. Can you come up with a list of the key considerations you might want to go through?
- If you'd like a Socratic list of 20 questions you ought to consider, try this link > Instructive use-case problems for clinical trial imagers